Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 MXvBdI9xfG:|aYOgRZN{[Xl? MVKzNE85OC9zNUCvNlUxKG6P MYiyOE81QC95MjDo M1q3[4lv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> NGTsO48zPTh6MkW1NC=>
MV411 MUjBdI9xfG:|aYOgRZN{[Xl? MYezNE85OC9zNUCvNlUxKG6P NFGxRnIzPC92OD:3NkBp MnjrbY5lfWOnczDkc5NmKGSncHXu[IFvfCCrbnT1Z5Rqd25ib3[gZZBweHSxc3nz NWriXpV{OjV6OEK1OVA>
MGC-803 Mnm5R4VtdCCYaXHibYxqfHliQYPzZZk> MlvxNE4yNTFyMECgcm0> NW\pXok1PzJiaB?= MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M4PiTlI2PTlyOEC1
SGC-7901 MnmyR4VtdCCYaXHibYxqfHliQYPzZZk> Ml3hNE4yNTFyMECgcm0> NFPyfpU4OiCq MnuzbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M2LMfFI2PTlyOEC1
MKN-28 M3L6PGNmdGxiVnnhZoltcXS7IFHzd4F6 M1vVWVAvOS1zMECwJI5O NULL[JFtPzJiaB?= NGHycGVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWm2[I5NOjV3OUC4NFU>
MGC-803 NH76[I1HfW6ldHnvckBCe3OjeR?= NYLq[YM4OC5zLUGwNFAhdk1? MnjPNlQhcA>? MkPRbY5lfWOnczDHNk9OKGOnbHytZ5lkdGViYYLy[ZN1 M3PMS|I2PTlyOEC1
HCT-116 MoHpSpVv[3Srb36gRZN{[Xl? NHzWbIo2OG6P M1:5blI1KGh? NXy4WnBTTE2VTx?= MnX1bY5lfWOnZDDHNE9IOSCjcoLld5Q> NVSzWZk3OjV{MUC3PVQ>
HT-29 NVP0OHZXTnWwY4Tpc44hSXO|YYm= MXK1NI5O NHv3UogzPCCq Mo[3SG1UVw>? NEC3blZqdmS3Y3XkJGcxN0dzIHHydoV{fA>? NYrRe2lXOjV{MUC3PVQ>
SCC25 MVLDfZRwgGmlaYT5JGF{e2G7 MXyxNE82OCCwTR?= MWSyOEBp NYC4Z406\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdiCmb4PlJIRmeGWwZHXueIx6 MnzKNlUzODV2M{C=
FUDA NV;y[oJ4S3m2b4jpZ4l1gSCDc4PhfS=> Mmm0NVAwPTBibl2= NH7jUpozPCCq NH\BTFBl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk> NH3kXnUzPTJyNUSzNC=>
Detroit562 NFvmSpREgXSxeHnjbZR6KEG|c3H5 NFPkUlQyOC93MDDuUS=> NFiyboMzPCCq MkXu[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NU\IPFVmOjV{MEW0N|A>
CAL27 NF\mOFdEgXSxeHnjbZR6KEG|c3H5 NWTjcWhxOTBxNUCgcm0> MVGyOEBp Mn3B[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 MWeyOVIxPTR|MB?=
DSH1 NVP6ZlBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTZibl2= NX:5cmdwOjR5OES4N|k>
SW-1710 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0Ro01UUN3ME22JI5O NVr4O|FXOjR5OES4N|k>
T24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLsRWJKSzVyPUegcm0> M2\McVI1Pzh2OEO5
RT112 M{HKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHpbG9LUUN3ME25JI5O MVmyOFc5PDh|OR?=
639-V NULXdJpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFyIH7N M3nKWlI1Pzh2OEO5
SCaBER MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknFTWM2OD1zMDDuUS=> Mnu3NlQ4QDR6M{m=
BFTC NGXCXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3STWM2OD1zNzDuUS=> M17Hd|I1Pzh2OEO5
J82 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7DXWtKSzVyPUG4JI5O MX6yOFc5PDh|OR?=
HT-1376 M1rCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\tdGlEPTB;MkGgcm0> MljENlQ4QDR6M{m=
647-V MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTnV3BKSzVyPUK3JI5O M2PPZVI1Pzh2OEO5
UM-UC3 NFTYZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jXcWlEPTB;M{Ogcm0> MonKNlQ4QDR6M{m=
LB831-BLC NFnNcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN2IH7N MmOyNlQ4QDR6M{m=
KU-19-19 MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPNTWM2OD1|NjDuUS=> NXPUXnIyOjR5OES4N|k>
35612 NW\IRoFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3vTWM2OD1|ODDuUS=> MkmyNlQ4QDR6M{m=
5637 NGnxfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTR2IH7N M2e3WlI1Pzh2OEO5
HT-1197 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm5TVdxUUN3ME21N{BvVQ>? M1vZNFI1Pzh2OEO5
MGH-U3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLIXYFKSzVyPUWzJI5O MoHjNlQ4QDR6M{m=
TCCSUP NYHuSpo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTqTWM2OD1zNEKgcm0> MU[yOFc5PDh|OR?=
RT4 NVTz[W46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWwSJRKSzVyPUG3N|Mhdk1? NGLaUJYzPDd6NEizPS=>
SW780 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj1[GVKSzVyPUO0OVEhdk1? MWSyOFc5PDh|OR?=
RKO NUjROZVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPsS5RKSzVyPUSgcm0> M1HtPFI1Pjh{N{S3
LS-411 N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fT[WlEPTB;NTDuUS=> NUfLR|BMOjR4OEK3OFc>
SW620 MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LITGlEPTB;ODDuUS=> M1K0V|I1Pjh{N{S3
HCT-15 NGnheXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfhTWM2OD16IH7N NXPkSFVMOjR4OEK3OFc>
HuTu-80 NX7hc2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfGbW42UUN3ME2xN{BvVQ>? MnLGNlQ3QDJ5NEe=
HCT 116 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLyTWM2OD1zNDDuUS=> NVPtcmRFOjR4OEK3OFc>
COLO-205 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXKTZlKSzVyPUG0JI5O MV[yOFY5Ojd2Nx?=
NCI-H747 M{SxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD1zNzDuUS=> M1HvUFI1Pjh{N{S3
COLO-678 NFzaTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJzIH7N MnnDNlQ3QDJ5NEe=
LoVo NFPnRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJ{IH7N NH;Ne5EzPDZ6Mke0Oy=>
LS-1034 M2HkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLvTWM2OD1|MTDuUS=> M3zFVVI1Pjh{N{S3
SNU-C2B MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkdotoUUN3ME20OUBvVQ>? MorBNlQ3QDJ5NEe=
LS-123 NV\hdWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISxcXFKSzVyPUezJI5O NGHzZZUzPDZ6Mke0Oy=>
SK-CO-1 M2HmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjXTWM2OD16MTDuUS=> MWOyOFY5Ojd2Nx?=
HCC2998 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7EfXpKSzVyPUGyPEBvVQ>? MmizNlQ3QDJ5NEe=
MDA-MB-231 NWjHcHlGTnWwY4Tpc44hSXO|YYm= MV6xNFAhdk1? NXroco1ROzBibXnu MUDpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? M1ntWVI1OjR6Mk[1
MDA-MB-435 NFvGbJdHfW6ldHnvckBCe3OjeR?= MkXCNVAxKG6P NU\rUW42OzBibXnu Mm\6bY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIFjJSk0y|rF? MnPrNlQzPDh{NkW=
BT-20  NVPhVW9{TnWwY4Tpc44hSXO|YYm= NF7iTHgyODBxMkWwJI5O Mn3ZNlQhcA>? MlzjdoV{fWy2ZXSgbY4h[SCmb4PlMYRmeGWwZHXueEBl\XO2YXLpcIl7[XSrb36gc4YhTUeIUjygTWdHNUmULDDNSXQtKGGwZDDDVmFH NX3vNYx[OjRzN{O1OFE>
MDA-MB-231 MkfpSpVv[3Srb36gRZN{[Xl? NYH4RXlTOTByIH7N NVT0[VZIOjRiaB?= NGmzdpJqdmirYnn0d{B1cGVibXnndoF1d3K7IHHu[EBqdn[jc3n2[UBk[XCjY3n0feKh NV2zeIxuOjRzN{O1OFE>
H82 M2XhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;MRpdKSzVyPUOwMlI4KG6P NWTLeVlrOjRzNk[1NFU>
GLC4 M3;MU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HheGlEPTB;MkCuOFchdk1? NEXVfFQzPDF4NkWwOS=>
H69 NG[w[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC0TWM2OD16Mz6zOkBvVQ>? MX2yOFE3PjVyNR?=
H128 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD14OT61OUBvVQ>? MkCwNlQyPjZ3MEW=
H146 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD1{OD61NUBvVQ>? NF3PVVMzPDF4NkWwOS=>
H187 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX5fpVbUUN3ME2yOE46QSCwTR?= NHjDSoEzPDF4NkWwOS=>
H526 NHrtTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnUTWM2OD1{MT62OEBvVQ>? MljxNlQyPjZ3MEW=
N592 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPuTWM2OD1zND6xNkBvVQ>? NWrv[ok4OjRzNk[1NFU>
H620 NFvNXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkKwTWM2OD1|Mj62O{BvVQ>? M3zV[|I1OTZ4NUC1
H792 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR3LkC3JI5O M2HxclI1OTZ4NUC1
H1173 NVq3UXJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XOR2lEPTB;MUKuOlIhdk1? M1vLNVI1OTZ4NUC1
AC3 NV\DXmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nEb2lEPTB;MkWuPUBvVQ>? NGTUeVIzPDF4NkWwOS=>
H82 Ml3aSpVv[3Srb36gRZN{[Xl? NFvmbmw{OCCwTR?= Mn:zO|IhcA>? MoXGbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 MU[yOFE3PjVyNR?=
GLC4 NInKVlRHfW6ldHnvckBCe3OjeR?= MmnoN|Ahdk1? MYC3NkBp MlO0bY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 M3fubVI1OTZ4NUC1
H146  MWPGeY5kfGmxbjDBd5NigQ>? NEXjcpI{OCCwTR?= NXq0cHlmPzJiaB?= NX6xOHpQcW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 M4TCTFI1OTZ4NUC1
OVCAR-5 M1X0[WNmdGxiVnnhZoltcXS7IFHzd4F6 MmDjNE0yODByIH7N MXm3NkBp MWXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NH:2clIzOzlyMEGzOi=>
OVCAR-8 NUPWR3hxS2WubDDWbYFjcWyrdImgRZN{[Xl? MU[wMVExODBibl2= NFW4Z2s4OiCq MoPIbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGXFbVEzOzlyMEGzOi=>
A1847 NITNZ2hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYWwMVExODBibl2= M32wSFczKGh? MWTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWTPUWcyOjN7MECxN|Y>
SKOV-3 M1X1VGNmdGxiVnnhZoltcXS7IFHzd4F6 NEn6PXIxNTFyMECgcm0> NH\PSlk4OiCq NID0b25qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVnJZXdTOjN7MECxN|Y>
OVCAR-5 MmPlRZBweHSxc3nzJGF{e2G7 M1zEU|ExNTFyMDDuUS=> NFvUOoIzPC92OD:3NkBp NWXISohkcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> NH[xbIszOzlyMEGzOi=>
OVCAR-8 MUHBdI9xfG:|aYOgRZN{[Xl? NFXtPYgyOC1zMECgcm0> M1PQ[|I1NzR6L{eyJIg> M3;zcIlv\HWlZYOgZZBweHSxc3nzJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62bIm= NXXN[nNJOjN7MECxN|Y>
A1847 Mnu1RZBweHSxc3nzJGF{e2G7 M{PrWlExNTFyMDDuUS=> NGHjTJYzPC92OD:3NkBp NFnxUlNqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 NVPXZZF6OjN7MECxN|Y>
H2228 M{HzNWNmdGxiVnnhZoltcXS7IFHzd4F6 MWOwMVExODBibl2= MXq3NkBp MV7JR|UxRTF|IH7N NXe0e2VUOjN3M{OyOlU>
H3122 M3jM[WNmdGxiVnnhZoltcXS7IFHzd4F6 M2DzZlAuOTByMDDuUS=> M1f5c|czKGh? MV;JR|UxRTFyIH7N NGixNlEzOzV|M{K2OS=>
K008 M1HFPWNmdGxiVnnhZoltcXS7IFHzd4F6 MorBTWM2OD14MDDuUS=> NU\mZ4lFOjN2MUi1NlM>
K028 NHTrVJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUnJR|UxRTh2IH7N MVeyN|QyQDV{Mx?=
K029 MkSwR4VtdCCYaXHibYxqfHliQYPzZZk> NVzPbHR6UUN3ME20OkBvVQ>? NW\ofG95OjN2MUi1NlM>
M23 NWDoUWVLS2WubDDWbYFjcWyrdImgRZN{[Xl? NH3EOG9KSzVyPUO3MlUhdk1? MYmyN|QyQDV{Mx?=
K033 MnzVR4VtdCCYaXHibYxqfHliQYPzZZk> M13kN2lEPTB;N{WuOUBvVQ>? NYK2W5hJOjN2MUi1NlM>
K008 NHv6PHNHfW6ldHnvckBCe3OjeR?= MXWyOVAhdk1? NHztTHMzPCCq M3TKU4lv\HWlZYOgS|Ih[XK{ZYP0 NEntemQzOzRzOEWyNy=>
K028 M4S0UGZ2dmO2aX;uJGF{e2G7 MknxNlUxKG6P MWSyOEBp MYDpcoR2[2W|IFeyJIFzemW|dB?= NIq3ZYkzOzRzOEWyNy=>
K029 NITpV5lHfW6ldHnvckBCe3OjeR?= MlKyNlUxKG6P MmTPNlQhcA>? M{D6TIlv\HWlZYOgS|Eh[XK{ZYP0 NYLM[lJ[OjN2MUi1NlM>
M23 M4HjeWZ2dmO2aX;uJGF{e2G7 M4TmVlI2OCCwTR?= M{G5[FI1KGh? NH\HN3pqdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=> M2frNVI{PDF6NUKz
K033 M2H1cmZ2dmO2aX;uJGF{e2G7 NInBcVQzPTBibl2= NHLXZ2EzPCCq M3T1Oolv\HWlZYOgZUBud2Snc4SgbY5kemWjc3WgbY4hTzFicH;weYxifGmxbh?= MmizNlM1OTh3MkO=
K008 NUDON3p[SXCxcITvd4l{KEG|c3H5 M4HRdVExOCCwTR?= M1\rTFczKGh? NEjCend{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| M1PYNlI{PDF6NUKz
K028 NUPGdnRISXCxcITvd4l{KEG|c3H5 MkTnNVAxKG6P MXO3NkBp M{jwcZNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NInMVpYzOzRzOEWyNy=>
K029 NG[zTHBCeG:ydH;zbZMhSXO|YYm= M2XOVFExOCCwTR?= NUTRb3NNPzJiaB?= NEHQR|h{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| MU[yN|QyQDV{Mx?=
M23 MWXBdI9xfG:|aYOgRZN{[Xl? M2HOPVExOCCwTR?= Mn7mO|IhcA>? MV7zbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{ NV;pc3JyOjN2MUi1NlM>
K033 MkX1RZBweHSxc3nzJGF{e2G7 NF7SbGoyODBibl2= Ml32O|IhcA>? M{DkcZNq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NFu5S3IzOzRzOEWyNy=>
RD MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG0TWM2OD16IH7N NVLERnN[OjN|MEO3OFE>
Rh41 NYe5OW1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFyLkSgcm0> NUHocXlSOjN|MEO3OFE>
Rh18 NYOwUVJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX3bVFOUUN3ME22MlIhdk1? MkXGNlM{ODN5NEG=
Rh30 MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTwTWM2OD13Lk[gcm0> NGTzOZAzOzNyM{e0NS=>
BT-12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;4W4lbUUN3ME2xOE4{KG6P NXTEOZJ6OjN|MEO3OFE>
CHLA-266 M1j1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTJTWM2OD1{Nz6xJI5O MVyyN|MxOzd2MR?=
TC-71 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vPPWlEPTB;ND61JI5O M4ezbVI{OzB|N{Sx
CHLA-9 Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjVTWM2OD12Lk[gcm0> NUj1T4tYOjN|MEO3OFE>
CHLA-10 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVwNzDuUS=> MmDNNlM{ODN5NEG=
CHLA-258 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjbWlEPTB;Nj60JI5O NYDFXnA6OjN|MEO3OFE>
SJ-GBM2 M1rCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrKTWM2OD1zMj65JI5O M4nHSlI{OzB|N{Sx
NB-1643 NVe1R|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLFUoxKSzVyPUeuOEBvVQ>? MlnPNlM{ODN5NEG=
NB-EBc1 NUXuVVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDufIVKSzVyPUG2Mlghdk1? M4TLTFI{OzB|N{Sx
CHLA-90 NWThd5o1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrBUopKSzVyPUKyMlMhdk1? NYHJSoVsOjN|MEO3OFE>
CHLA-136 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTJ|LkKgcm0> NEnLUJczOzNyM{e0NS=>
NALM-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvhTWM2OD1zMT63JI5O MkHjNlM{ODN5NEG=
COG-LL-317 NGPMO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofOTWM2OD12LkSgcm0> NF\mTGszOzNyM{e0NS=>
RS4;11 NVi1NGxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|LkWgcm0> MViyN|MxOzd2MR?=
MOLT-4 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFyLk[gcm0> NXLjN3RsOjN|MEO3OFE>
CCRF-CEM (1) M2Cyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInUO4dKSzVyPUGyMlUhdk1? M{DWTVI{OzB|N{Sx
CCRF-CEM (2) MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLmTWM2OD15LkKgcm0> NVm5[otGOjN|MEO3OFE>
Kasumi-1 NGPYflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPVcWJKSzVyPUWuPEBvVQ>? NVvQbZhmOjN|MEO3OFE>
Karpas-299 NWjZWY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTlwNjDuUS=> NVHWZ2c1OjN|MEO3OFE>
Ramos-RA1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXTWM2OD15LkSgcm0> M{DaXFI{OzB|N{Sx
LNCaP M3HIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W2V2lEPTB;ODDuUS=> MljJNlMyPTJyMES=
VCaP NUXxdWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdibl2= M3fqZVI{OTV{MEC0
H1355 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\HTWM2OD13IH7N M3jobVI{ODF{MkS4
H157 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL5TWM2OD15IH7N NX;PNHlyOjNyMUKyOFg>
H460 NFzSOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jWfmlEPTB;ODDuUS=> MVWyN|AyOjJ2OB?=
IA-LM NYnFdHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPKdmlZUUN3ME2xNEBvVQ>? MlzRNlMxOTJ{NEi=
HOP-62 NXq3Unk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLLT4drUUN3ME2xNUBvVQ>? M3nhOlI{ODF{MkS4
H23 M4jKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMTWM2OD1zMTDuUS=> M1vITFI{ODF{MkS4
H2030 M2K3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{IH7N NXK1UpJlOjNyMUKyOFg>
H441 NVPSOXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF2IH7N MoPnNlMxOTJ{NEi=
H2212 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF5IH7N Mk[4NlMxOTJ{NEi=
SK-LU-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD4N3kzUUN3ME2xPEBvVQ>? MWmyN|AyOjJ2OB?=
H2009 NGfIUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPod2FKSzVyPUG5JI5O NVHuNXR2OjNyMUKyOFg>
H1792 NF[3flJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\jWlV7UUN3ME2yNEBvVQ>? MoPINlMxOTJ{NEi=
COR-L23 NEO3T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL6VmNKSzVyPUKyJI5O M1rNSlI{ODF{MkS4
H727 M3;OZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\JdHBKSzVyPUK4JI5O NGO0PGkzOzBzMkK0PC=>
H1734 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITmTWhKSzVyPUK4JI5O MlrvNlMxOTJ{NEi=
H358 M{S5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ7IH7N NV2zNmhJOjNyMUKyOFg>
A549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR|IH7N MViyN|AyOjJ2OB?=
H2122 NHK4eoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK0cm1KSzVyPUWzJI5O NEi2OYkzOzBzMkK0PC=>
Calu-1 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPkXGI2UUN3ME21PEBvVQ>? NXjGPZNZOjNyMUKyOFg>
Calu-6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zKbWlEPTB;NkSgcm0> Mn3zNlMxOTJ{NEi=
NCI-H1975 NF3GPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLROIFSPDhiaB?= NHz2SWhKSzVyPUG2JI5O M2\LcVIzOTR2Nk[1
NCI-H1975 NXrVSJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rSSVczKGh? M3\UcmlEPTB;ODDuUS=> M2jPZ|IzOTR2Nk[1

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
5% DMSO+45% PEG 300+ddH2O
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02192541 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 9, 2014 Phase 1
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 --
NCT02389751 Active, not recruiting Esophageal Cancer M.D. Anderson Cancer Center|Synta Pharmaceuticals Corp. April 2015 Phase 1
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2
NCT02272478 Recruiting Acute Myeloid Leukaemia|Myelodysplastic Syndrome Cardiff University|Cancer Research UK October 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID